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OBJECTIVE: The goal of the present study was to estimate the risk ratio of herpes zoster among systemic lupus
erythematosus patients after disease onset compared with a cohort of patients without systemic lupus
erythematosus over a three-year period.
METHODS: A nationwide population-based cohort study using the National Health Insurance Research Database
identified 10,337 new cases of systemic lupus erythematosus as the study cohort. In addition, 62,022 patients
without systemic lupus erythematosus, who were matched for age, gender, and date of systemic lupus
erythematosus diagnosis, were used as the comparison cohort. These cohorts were followed-up for three years. A
Cox proportional hazard regression was performed to estimate the risk ratio of herpes zoster, with adjustments for
age, gender, level of insurance, urbanization level, geographic region, comorbid medical conditions, average daily
dosage of corticosteroids, and the use of immune-modulation agents.
RESULTS: Compared to patients without systemic lupus erythematosus, the crude risk ratio and adjusted risk ratio of
herpes zoster among systemic lupus erythematosus patients were 7.37 (95% confidence interval 6.75-8.04) and 2.45
(95% confidence interval 1.77-3.40), respectively. Stratified by gender, the adjusted risk ratio of herpes zoster was
2.10 (95% confidence interval 1.45-2.99) in women and 7.51 (95% confidence interval 2.89-19.52) in men. Stratified
by age, the adjusted risk ratio peaked in systemic lupus erythematosus patients who were aged 18 to 24 years (risk
ratio 8.78, 95% confidence interval 3.08-24.97).
CONCLUSION: Based on nationwide population-based data, there is an increased risk of herpes zoster in systemic
lupus erythematosus patients compared with non-systemic lupus erythematosus patients, particularly among males
and patients aged 18 to 24 years. Further research on the associated risk factors for herpes zoster in systemic lupus
erythematosus patients is needed.
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INTRODUCTION
Herpes zoster (HZ) is characterized by debilitating
painful vesicular eruptions in a dermatomal distribution
that are caused by the reactivation of a latent varicella zoster
virus (VZV) infection.1 This disease is commonly observed
in the elderly, in immuno-compromised hosts, and in
patients with systemic lupus erythematosus (SLE).2-5
Cutaneous vesicles can be complicated by a bacterial
super-infection, and the dissemination of HZ may be life-
threatening.3 Post-herpetic neuralgia in the affected areas is
the most common complication, which can persist for
months or years. The incidence of HZ in the general
population is 1.2 to 4.9 cases per 1000 person-years,
depending on the ethnic group.6-7 The reported incidence
of HZ in SLE patients is significantly greater than the
incidence in the general population, ranging from 16 to 22
cases per 1000 patient-years in large cohort studies.2-3,8
The greater incidence of HZ infection in SLE has been
shown to be related to abnormal T-cell-mediated cytotoxi-
city that is aggravated by the concomitant use of glucocor-
ticoids and immuno-suppressants.4,9-10 Disease activity,
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lupus nephritis, and positive anti-Sm antibodies have been
reported to be valuable risk factors for HZ in SLE patients.5
However, although the greater frequency of HZ infection in
SLE patients is well recognized, a population-based cohort
study has not yet been conducted. Moreover, the impact of
age and gender on the risk of HZ in SLE patients remains
unclear.
The purpose of the present study was to examine the
estimated risk ratio for HZ among SLE patients in the three-
year period after disease onset compared to that of a cohort of
patients without SLE during the same time period using the
Taiwanese National Health Insurance Research Database
(NHIRD).
PATIENTS AND METHODS
Data source
The data source for the present study was the NHIRD,
which includes inpatient and ambulatory care claims from
1996 to 2006. The National Health Insurance Program of the
Bureau of National Health Insurance (BNHI) was imple-
mented on March 1, 1995 and has since covered more than
98% of the population. The BNHI’s computerized compre-
hensive database, including all of the medical claims for
ambulatory care services and hospitalization, can facilitate a
nationwide population-based cohort study. The NHIRD
established a registry system for "Catastrophic Illnesses",
including cancer, chronic mental illness, end-stage renal
disease, congenital illness, and several autoimmune diseases
such as SLE. The BNHI performs routine validations of the
diagnoses by reviewing the original medical charts of all of
the patients who applied for catastrophic illness registration.
In Taiwan, the American College of Rheumatology classifica-
tion criteria for SLE was used to validate the SLE diagnosis
using the versions published in 1982 or 1997 based on the
timing of making SLE diagnosis. Because the present study
enrolled SLE patients solely from this particular registry, the
accuracy of the SLE diagnosis was not a concern.
The NHIRD established a representative database from
the entire set of enrollees by randomly selecting 1,000,000
subjects. The present study used all of the claims data for
these 1,000,000 subjects during the period of 1996 to 2006 to
select a comparison cohort of patients without SLE. This
cohort matched the study cohort for age, gender, and the
date of the first ambulatory visit after the SLE diagnosis.
Because the NHIRD consisted of de-identified secondary
data that were released to the public for research purposes,
the present study was exempted from a full review by the
Internal Review Board.
Study samples
The present study was a retrospective cohort study that
consisted of a study cohort and a comparison cohort. The
study cohort consisted of SLE patients (International
Classification of Diseases, 9th Revision, Clinical Modification
[ICD9-CM] Code 710.0) in Taiwan from the registry of
catastrophic illness patients during the period of 1996 to
2006. The index date for the study cohort was identified as the
date of the first-time ambulatory care visit that had a diagnosis
code for SLE during that period. To identify new SLE cases,
those who had an index date before January 1, 1998 were
excluded. The SLE patients who were followed-up for less
than three years were also excluded from the present study. To
minimize the possibility of enrolling SLE patients with an
episode of HZ before the index date or with a diagnosis code
for HZ for prescribing medications for post-herpetic neuralgia
after the index date, patients with any ambulatory visit for HZ
(ICD9-CM code 053) within one year before the index date
were excluded from the present study. The study cohort
consisted of 10,337 SLE patients.
The comparison cohort was selected from a 1,000,000
representative cohort. Patients with an SLE diagnosis in any
of the claims data during the time period of 1996 to 2006
were excluded from the present study. Patients from the
registry of beneficiaries (six for every patient in the study
cohort) were then randomly extracted as the comparison
cohort, matching the study cohort for the age at SLE onset
(i.e., 1-17, 18-24, 25-34, 35-44, 45-54, 55-64, .64 years),
gender, and the year of the index date. The date of the first-
time ambulatory visit within one year of the index date was
selected as the index date for the comparison cohort.
Patients with less than three years of ambulatory visit
records after the index date were excluded from the present
study. Patients with an ambulatory visit for HZ within one
year before the index date were also excluded. The
comparison cohort included 62,022 patients without SLE.
The potential confounding variables included the level of
insurance as the economic index, the urbanization level, the
geographic region (northern, central, southern, or eastern)
of the patients, the types of medications, the presence of co-
morbid medical diseases, and the Charlson co-morbidity
index (CCI), as adapted by Deyo.11 The level of insurance
was transformed to ordinal variables according to the 25th,
50th and 75th percentiles. In Taiwan, the urbanization levels
were stratified into seven clusters, ranging from level one
(most urbanized) to level seven (least urbanized).12
However, because the patient numbers in levels five
through seven were small in both cohorts, these three levels
were combined into one level (level five). The presence of
prescription medication that was adjusted in the regression
model included the average daily steroid dose (i.e., 0, ,10,
10-20 and .20 mg prednisolone equivalent) and the use of
azathioprine, cyclophosphamide, mycophenolate, cyclos-
porin, methotrexate, or hydroxychloroquine.
Diabetes mellitus (ICD9-CM code 250), lymphoma (ICD9-
CM codes 200-202), leukemia (ICD9-CM codes 204-208),
breast cancer (ICD9-CM codes 174-175), liver cancer (ICD9-
CM code 155), and HIV/AIDS (ICD9-CM code 042) were co-
morbid medical disorders because previous studies have
suggested that these disorders are risk factors for HZ.7 The
CCI was also calculated for the adjustments for possible
confounding co-morbidities. Using the diagnosis codes in
two or more ambulatory claims that were made six months
before or after the index date, the co-morbidities were
identified, and the CCI was calculated.
Statistical analysis
To examine the unadjusted comparisons, a t-test was used
for the normally distributed continuous variables, and a
Pearson x2 test was used to analyze the categorical
variables. The correlations between the variables were
analyzed using Pearson’s correlation coefficients. The
Kaplan-Meier method was performed to estimate the
three-year HZ-free survival rates, and the log-rank test
was used to examine the differences in the risk of HZ
between the two cohorts. Cox proportional hazard regres-
sions were used to compute the crude and adjusted risk
ratios (RR) with a 95% confidence interval (95% CI). A
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two-tailed p,0.05 was considered to be statistically sig-
nificant. All of the analyses were conducted using the
Statistical Package for the Social Sciences (SPSS) for
Windows, Version 13.0 (SPSS, Inc., Chicago, Illinois).
RESULTS
The socio-demographic data between the study and
comparison cohorts are shown in Table 1. The female to
male ratio was 9:1, and the mean age (¡SD) was 34.8¡14.3
years for the study cohort and 34.8¡15.0 years for the
control cohort (p= 0.678). Approximately two-thirds of
the patients were aged 18 to 44 years. The distributions of
the insurance levels, urbanization levels, and geographic
regions of residence were significantly different between
these two cohorts.
The co-morbid medical conditions and prescription
medications of the two cohorts are shown in Table 2. The
study cohort exhibited greater proportions of patients with
lymphoma, leukemia, liver cancer, and renal disease. In
addition, greater proportions of patients were found to
receive medication for systemic corticosteroids, azathiopr-
ine, cyclophosphamide, methotrexate, cyclosporin, and
hydroxychloroquine compared to the control cohort. The
study cohort had a significantly greater CCI; however, this
cohort had a lower proportion of patients with diabetes
mellitus.
Among the SLE patients, age was found to be negatively
correlated with average daily corticosteroid dose (Pearson
correlation coefficient -0.118, p,0.001), and age was found
to be positively correlated with CCI (Pearson correlation
coefficient 0.106, p,0.001) (data not shown). Thus, the
younger groups of SLE patients were administered larger
average daily doses of corticosteroids (Table 3).
The incidence rates with a 95% CI for HZ were 37.7 (35.5-
40.0) cases per 1000 patient-years in the SLE patients and 5.1
(4.8-5.4) cases per 1000 patient-years in the non-SLE controls
(Table 4). In the controls, the age-specific incidence rates
were higher in the older groups, irrespective of gender. In
contrast, among the SLE patients, the incidence rates peaked
in the youngest group (,18 years), regardless of gender.
Patients with SLE had a significantly greater risk of HZ
than the patients in the control cohort (RR 7.37, 95% CI 6.75-
8.04, p,0.001) (Table 5). After adjusting for the possible
confounding factors that are shown in Tables 1 and 2, the
SLE patients had a significantly greater risk of HZ than the
control cohort (RR 2.45, 95% CI 1.77-3.40, p,0.001). After
stratifying by age, the adjusted RRs for HZ in the SLE
patients compared with those of the non-SLE controls
reached statistical significance in most of the age groups
and peaked in those aged 18 to 24 years. Stratified by
gender, the male SLE patients exhibited larger RRs for HZ
than the female SLE patients (RR 7.51, 95% CI 2.89-19.52 vs.
RR 2.10, 95% CI 1.48-2.99).
A log-rank test revealed that the SLE patients had a
significantly lower risk of three-year HZ-free survival rates
than the non-SLE controls (p,0.001). The duration between
the index date and the date of HZ onset for the SLE patients
ranged from one day to 1094 days, and the median and
mean (¡ SD) duration were 436 days and 476¡331 days,
respectively. The survival curves for the two cohorts, which
were determined using the Kaplan-Meier survival analysis,
are illustrated in Figure 1.
DISCUSSION
The present study has determined the incidence occur-
rences for HZ and the risk ratios for HZ among patients
with SLE compared with those without SLE using nation-
wide population-based data. This study is the largest and
first nationwide population-based cohort study regarding
HZ infections in SLE patients. The incidence rate for HZ
among the non-SLE patients (5.1 cases per 1000 patient-
years) is consistent with those among the normal population
that were reported in previous studies (1.2 to 4.9 cases per
1000 person-years).6-7 However, the incidence rate for HZ
among the SLE patients in the present study (37.7 cases per
1000 patient-years) was larger than those among the SLE
patients in previous cohort studies (16-22 cases per 1000
patient-years).2-3,8 Using an administrative database instead
of reviewing medical records prevents underestimation. The
adjusted RR for HZ in the SLE cohort was 2.45, which is in
agreement with a previous study in Taiwan that reported
that patients with HZ had a rate ratio of 2.12 for co-morbid
SLE compared with that of controls.7 However, this result
was further adjusted for the presence of prescription
medication and the CCI, which can minimize the potential
confounding effects of concomitant medications and other
co-morbidities.
Previous studies have indicated that the incidence of HZ
infection increases with age in the general population.7,13
The risk of HZ is greatest in subjects who are over 80 years
of age and lowest in those who are younger than 20 years of
age.13 In addition, the annual risk of HZ infection increases
significantly in the geriatric population, with approximately
two-thirds of individuals who are over 60 years developing
Table 1 - Demographic data of patients with systemic
lupus erythematosus (SLE) and of the control cohort.
SLE patients
(n = 10337)
Non-SLE Patients
(n = 62022) p-value
Variable
Gender 1.000
Male 1052 (10.2) 6312 (10.2)
Female 9285 (89.8) 55710 (89.8)
Age groups, years 1.000
,18 955 (9.3) 5730 (9.3)
18-24 1844 (17.8) 11064 (17.8)
25-34 2724 (26.4) 16344 (26.4)
35-44 2342 (22.7) 14052 (22.7)
45-54 1438 (13.9) 8628 (13.9)
55-64 650 (6.3) 3900 (6.3)
.64 384 (3.7) 2304 (3.7)
Urbanization level ,0.001
1 3824 (37.0) 25220 (40.7) ,0.001
2 3444 (33.3) 20612 (33.2) 0.867
3 1497 (14.5) 7929 (12.8) ,0.001
4 921 (8.9) 4911 (7.9) 0.001
5 651 (6.3) 3350 (5.4) ,0.001
Geographic region ,0.001
Northern 4943 (47.8) 33484 (54.0) ,0.001
Central 2745 (26.6) 13889 (22.4) ,0.001
Southern 2524 (24.4) 13783 (22.2) ,0.001
Eastern 125 (1.2) 866 (1.4) 0.130
Insurance level (NT$) ,0.001
0-6360 3047 (29.5) 15307 (24.2) ,0.001
6361-15500 2319 (22.4) 15782 (25.4) ,0.001
15501-20300 2583 (25.0) 15437 (24.9) 0.830
.20300 2388 (23.1) 15766 (25.4) ,0.001
Values are the number of patients (percentage), unless otherwise indicated.
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HZ.14 Consistent with data from previous studies, the
incidence rate among patients without SLE is greatest in
subjects who are older than 64 years of age and lowest in
subjects who are younger than 18 years of age. However, the
current study reveals that the incident rate for HZ is greater
in groups of younger SLE patients. Possible explanations for
this finding include an increase in the SLE disease severity,
larger doses of corticosteroids and/or immuno-suppressive
agents, or a larger number of co-morbid conditions in
younger SLE patients. Given the positive correlation
between age and CCI in the current study, the last
explanation is less likely to be the the cause of increased
rate of HZ among younger SLE patients. The elderly lupus
population has been reported to exhibit a greater number of
benign disease courses,15-16 and physicians may prescribe
lower doses of corticosteroid for elderly SLE patients
because of a lower level of disease activity or a higher risk
of drug-related complications, such as steroid-induced
diabetes, atherosclerosis, or immuno-suppressive related
infection. Thus, the first two reasons are more likely than the
last one to lead to the larger incident rates that have been
observed in younger SLE patients.
The crude RR for HZ is greater in young SLE patients and
peaks in the youngest group of these patients. However,
after an adjustment for the presence of prescription
medication and co-morbid conditions, this trend seems to
disappear. The adjusted RR for HZ is greatest in the SLE
patients who are aged 18 to 24 years and lowest in those
aged 45 to 54 years. It is not known whether this finding is
related to SLE severity.
Previous studies have demonstrated that men have a lower
incidence rate of HZ than women.12 However, the present
study indicates that the incidence rate for HZ in male SLE
patients is not lower than that in female SLE patients (39.2
cases per 1000 patient-years vs. 37.6 cases per 1000 patient-
years). Compared with non-SLE patients, the adjusted RR for
an HZ infection in male SLE patients (RR 7.51, 95% CI 2.89-
19.52, p,0.001) is also greater than that in female SLE patients
(RR 2.10, 95% CI 1.48-2.99, p,0.001). Despite these conflicting
Table 2 - Comparison of co-morbidities and prescription medications between the SLE patients and the non-SLE
controls.
SLE Patients
(n = 10337)
Non-SLE Patients
(n = 62022) p-value
Variables
Co-morbid medical conditions
Diabetes 218 (2.1) 1565 (2.5) 0.012
Lymphoma 22 (0.2) 18 (0.0) ,0.001
Leukemia 9 (0.1) 10 (0.0) ,0.001
Breast cancer 17 (0.2) 154 (0.3) 0.104
Liver cancer 11 (0.1) 18 (0.0) ,0.001
HIV/AIDS 0 (0.0) 2 (0.0) 0.564
Charlson co-morbidity index, mean ¡ SD 7.83 ¡ 1.22 0.23 ¡ 0.81 ,0.001
Prescription medication
Systemic corticosteroid 9695 (93.8) 30254 (48.8) ,0.001
Prednisolone equivalent dose (mg/day) ,0.001
No use 648 (6.3) 32046 (51.7)
0-10 6588 (63.7) 29946 (48.3)
10-20 2300 (22.3) 26 (0.0)
.20 801 (7.7) 4 (0.0)
Azathioprine 3661 (35.4) 29 (0.0) ,0.001
Cyclophosphamide 2287 (22.1) 106 (0.2) ,0.001
Methotrexate 859 (8.3) 140 (0.2) ,0.001
Cyclosporin 250 (2.4) 28 (0.0) ,0.001
Hydroxychloroquine 8179 (79.1) 199 (0.3) ,0.001
Values are the number of patients (percentage), unless otherwise indicated.
Table 3 - Average daily prednisolone (Pd) equivalent dose
and Charlson co-morbidity index (CCI) for the SLE patients
and non-SLE controls, as stratified by age.
Pd equivalent (mg/day) CCI
SLE
Patients
Non-SLE
Patients
SLE
Patients
Non-SLE
Patients
Age, years
,18 13.53 0.05 7.89 0.04
18-24 10.44 0.06 7.76 0.06
25-34 9.26 0.07 7.70 0.09
35-44 7.21 0.08 7.72 0.21
45-54 6.49 0.13 7.94 0.46
55-64 5.41 0.20 8.20 0.66
.64 5.54 0.16 8.48 1.01
Values are the means of the groups.
Table 4 - Incidence rates (number of cases per 1000
patient-years) of herpes zoster in the SLE patients and
non-SLE controls, stratified by age and gender during the
three-year follow-up period*.
SLE Patients Non-SLE Patients
All Female Male All Female Male
Age, years
All 37.7 37.6 39.2 5.1 5.2 4.7
,18 58.1 57.8 59.8 2.2 2.4 1.3
18-24 37.5 38.8 27.6 3.2 3.3 2.5
25-34 30.0 29.5 35.4 2.9 2.8 3.8
35-44 37.7 35.4 39.2 4.8 4.9 3.9
45-54 42.5 43.7 31.0 10.1 10.5 7.0
55-64 34.1 32.1 49.2 10.0 10.0 9.7
.64 46.9 45.1 53.8 12.8 13.0 12.0
*Values are the means of the groups.
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data, male SLE patients exhibit a greater level of renal
involvement and a worse prognosis19-21 and may have an
increased disease severity and a higher risk of HZ infection.
In Taiwan, the universal varicella vaccine was introduced
for children who were born after mid-2002. However, all of
the study subjects in the present study were born before
August of 2002; therefore, the relative risk of HZ infection
among SLE patients compared with non-SLE patients may
not be influenced by the universal varicella vaccination
policy in Taiwan. The finding of a higher risk of HZ in SLE
patients raises the issue of whether active immunization
should be used in these patients. A randomized controlled
trial has shown that zoster vaccine, a live attenuated
vaccine, is effective in preventing HZ and post-herpetic
neuralgia in the elderly.17 However, there is limited
evidence regarding the vaccine’s use in SLE patients.18
Concomitant immuno-suppressive agents may reduce the
efficacy of vaccines, and whether there are complications
associated with this vaccination in the pathogenesis of SLE
remain unclear.18 Further studies are needed to investigate
the safety and efficacy of the varicella vaccination in SLE
patients.
The present study has three advantages. First, the use of
an administrative database prevents under-reporting of the
number of medical visits.22 Previous studies on the
incidence of HZ in SLE patients have mainly used medical
record reviews at the selected institutions.2-5,8-9 Second, this
nationwide population-based study avoids a selection bias.
Third, the present study has adjusted for many important
confounding factors, including age, gender, economic
status, prescribed medication, and co-morbidities.
Although race was not included in these adjustments,
greater than 98% of Taiwan’s residents are of Chinese Han
ethnicity. This homogenous population makes the results of
the present study unlikely to be confounded by race.
However, this population also limits the generalization of
the study results to other ethnic groups.
The present study also has several limitations. First,
the accuracy of the diagnoses, which are based on the
Table 5 - Crude and multivariate adjusted risk ratios (RRs)
with 95% confidence intervals for herpes zoster in the
SLE patients and non-SLE controls, as stratified by age
and gender, during the three-year follow-up period.
Crude RR of HZ p-value Adjusted RR of HZ p-value
Age, years
all 7.37 (6.75-8.04) ,0.001 2.45 (1.77-3.40) ,0.001
,18 25.81 (18.08-36.84) ,0.001 4.71 (1.41-15.70) 0.012
18-24 11.81 (9.32-14.97) ,0.001 8.78 (3.08-24.97) ,0.001
25-34 10.43 (8.46-12.86) ,0.001 3.04 (1.26-7.33) 0.013
35-44 7.40 (6.14-8.93) ,0.001 2.26 (1.06-4.82) 0.034
45-54 4.19 (3.46-5.09) ,0.001 1.79 (0.88-3.65) 0.108
55-64 3.45 (2.54-4.69) ,0.001 2.90 (1.12-7.49) 0.028
.64 3.65 (2.58-5.17) ,0.001 2.33 (0.79-6.87) 0.126
Gender
Female 7.27 (6.63-7.96) ,0.001 2.10 (1.48-2.99) ,0.001
Male 8.35 (6.33-11.02) ,0.001 7.51 (2.89-19.52) ,0.001
Multivariable regression models adjusted for the variables listed in
Tables 1 and 2, including gender, age, insurance level, urbanization level,
geographic region, co-morbidities, Charlson co-morbidity index, and
prescription medications.
Figure 1 - The survival curves determined using the Kaplan-Meier survival analysis for herpes zoster among SLE patients and non-SLE
patients during the three-year follow-up period.
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administrative data reported by physicians, may be a
concern. Although the Bureau of National Health Insurance
routinely samples patient charts to randomly cross-check the
claims from all of the hospitals, a bias due to miscoding and
misclassification may occur. Second, the lack of information
about self-treatment with over-the-counter medications in
the NHIRD may lead to underestimation of HZ. Third, an
information bias may arise if the SLE patients have a greater
tendency to visit physicians instead of using self-treatment
with over-the-counter medications for cutaneous problems
than the non-SLE patients. Another information bias may
occur if physicians are more alert to the diagnosis of HZ in
patients with SLE than in patients without SLE. Lastly, the
administrative database cannot offer information about the
SLE disease severity, which may also be a confounding factor
for the results of the present study.
In conclusion, this nationwide population-based study
shows that the relative risk of developing HZ in SLE
patients after disease onset in a three-year follow-up period
is 2.45 compared with that of non-SLE patients. Among the
SLE patients, the RR for HZ is greater in males and peaks in
those aged 18 to 24 years. Further investigation of the
associated risk factors for HZ in SLE patients is needed.
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